Late-onset neutropenia after rituximab in ANCA-associated vasculitis

Scandinavian Journal of Rheumatology

Volumn 45, Issue 5, 2016, Pages 404-407

  Knight, Ann ^a   Sundstrom Y ^b   Borjesson O ^c   Bruchfeld, A ^c   Malmstrom V ^b   Gunnarsson, I ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; CREATININE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; RITUXIMAB; ANTIRHEUMATIC AGENT;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBIOTIC THERAPY; ARTICLE; CREATININE BLOOD LEVEL; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LATE ONSET NEUTROPENIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL COUNT; ONSET AGE; PRIORITY JOURNAL; RETREATMENT; TREATMENT DURATION; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHEMICALLY INDUCED; GRANULOMATOSIS WITH POLYANGIITIS; RETROSPECTIVE STUDY;

ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIRHEUMATIC AGENTS; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 84983415009     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2016.1138318     Document Type: Article

References (14)

1. T.Kelesidis, G.Daikos, D.Boumpas, S.Tsiodras Does rituximab increase the incidence of infectious complications? Int J Infect Dis 2011;15:2–16.
2. O.Wolach, O.Bairey, M.Lahav. Late onset neutropenia after rituximab treatment:case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308–18.
3. G.S.Breuer, M.Ehrenfeld, I.Rosner, A.Balbir-Gurman, D.Zisman, S.Oren, et al. Late-onset neutropenia following rituximab treatment for rheumatologic conditions. Clin Rheumatol 2014;33:1337–40.
4. D.Tesfa, S.Ajeganova, H.Hägglund, B.Sander, B.Fadeel, I.Hafström, et al. Late-onset neutropenia following rituximab therapy in rheumatic disease:association with B – lymphcyte depletion and infections. Arthritis Rheum 2011;8:2209–14.
5. D.Tesfa, T.Gelius, B.Sander, E.Kimby, B.Fadeel, J.Palmblad, et al. Late-onset neutropenia associated with rituximab therapy; evidence for maturation arrest at (pro-) myleocyte stage of granulopoesis. Med Oncol 2008;25:374–9.
6. B.Terrier, M.Ittah, L.Tourneur, F.Louache, V.Soumelis, F.Lavie, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007;92:e20–3.
7. C.Grant, W.H.Wilson, K.Dunleavy. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2011;18:49–54.
8. O.Flossmann, P.Bacon, K.de Groot, D.Jayne, N.Rasmussen, P.Seo, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 2007;66:283–92.
9. K.Dunleavy, K.Tay, W.H.Wilson. Rituximab- associated neutropenia. Semin Hematol 2010;47:180–6.
10. W.F.PendergraftIII, F.B.Cortazar, J.Wenger, A.P.Murphy, E.P.Rhee, K.A.Laliberte, et al. Long term maintenance therapy using rituximab-induced B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 2014;9:736–44.
11. E.Besada, W.Koldingsnes, J.Nossent. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab:a case review analysis from a single center. QJM 2012;105:545–50.
12. O.Wolach, O.Shpilberg, M.Lahav. Neutropenia after rituximab treatment:new insights on a late complication. Curr Opin Hematol 2012;19:32–8.
13. T.Vallerskog, M.Heimburger, I.Gunnarsson, W.Zhou, M.Wahren-Herlenius, C.Trollmo, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167.
14. F.Lavie, C.Miceli-Ricard, M.Ittah, J.Sellam, J.-E.Gottenberg, X.Mariette. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab treatment:insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700–3.